Intensity Therapeutics

INTSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$11.244 M

$4.16 -2.12%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$11.6M

Loss-making

Shares outstanding

2,540,518

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#143PluriPLUR$19.6M
#144Passage BIOPASG$14.1M
#145Intensity TherapeuticsINTS$11.2M
#146BioCardiaBCDA$11.1M
#147Senti BiosciencesSNTI$11.0M

Where these numbers come from

Share counts and financials for Intensity Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.